A randomized exploratory trial of an alpha-7 nicotinic receptor agonist (TC-5619) for cognitive enhancement in schizophrenia

Neuropsychopharmacology

Volumn 38, Issue 6, 2013, Pages 968-975

  Lieberman, Jeffrey A ^a   Dunbar, Geoffrey ^b   Segreti, Anthony C ^b   Girgis, Ragy R ^a   Seoane, Frances ^b   Beaver, Jessica S ^b   Duan, Naihua ^a   Hosford, David A ^b  

^a Columbia College of Physicians and Surgeons ^*  (United States)

^b Clinical Development and Regulatory Affairs Targacept   (United States)

Author keywords

alpha7 nicotinic receptor; clinical trial; cognitive function; negative symptoms; schizophrenia; TC 5619

Indexed keywords

NICOTINIC AGENT; PLACEBO; QUETIAPINE; RISPERIDONE; TC 5619; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; BODY TEMPERATURE; CALGARY DEPRESSION SCALE; CLINICAL GLOBAL IMPRESSION SCALE; CONSTIPATION; CONTROLLED STUDY; DECREASED APPETITE; DERMATITIS; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG EFFECT; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG WITHDRAWAL; EXECUTIVE FUNCTION; EXPLORATORY RESEARCH; FEMALE; GASTRITIS; GASTROENTERITIS; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MAZE TEST; MONOTHERAPY; NAUSEA; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; PSYCHOLOGIC TEST; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; SIDE EFFECT; SOMNOLENCE; TIME TO MAXIMUM PLASMA CONCENTRATION; WORKING MEMORY;

ADOLESCENT; ADULT; ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTOR; ANTIPSYCHOTIC AGENTS; BENZOFURANS; FEMALE; HUMANS; INDIA; MALE; MIDDLE AGED; NICOTINIC AGONISTS; NOOTROPIC AGENTS; QUINUCLIDINES; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; UNITED STATES; YOUNG ADULT;

EID: 84878590414     PISSN: 0893133X     EISSN: 1740634X     Source Type: Journal    
DOI: 10.1038/npp.2012.259     Document Type: Article

References (39)

1. Addington J, Addington D (1993). Premorbid functioning, cognitive functioning, symptoms and outcome in schizophrenia. J Psychiatry Neurosci 18: 18-23.
2. American Psychiatric Association (2000). Diagnostic and Statistical Manual of Mental Disorders. 4th edn, Text Revision edn American Psychiatric Association: Washington, DC
3. Buchanan RW, Conley RR, Dickinson D, Ball MP, Feldman S, Gold JM et al (2008). Galantamine for the treatment of cognitive impairments in people with schizophrenia. Am J Psychiatry 165: 82-89.
4. Buchanan RW, Schwarcz R (2011). Alpha7 nicotinic receptor agonists as cognitive treatments: is less (or less often) more? Biol Psychiatry 69: 5-6.
5. Castner SA, Smagin GN, Piser TM, Wang Y, Smith JS, Christian EP et al (2011). Immediate and sustained improvements in working memory after selective stimulation of alpha7 nicotinic acetylcholine receptors. Biol Psychiatry 69: 12-18.
6. Court J, Spurden D, Lloyd S, McKeith I, Ballard C, Cairns N et al (1999). Neuronal nicotinic receptors in dementia with Lewy bodies and schizophrenia: alpha-bungarotoxin and nicotine binding in the thalamus. J Neurochem 73: 1590-1597.
7. de Leon J, Dadvand M, Canuso C, White AO, Stanilla JK, Simpson GM (1995). Schizophrenia and smoking: an epidemiological survey in a state hospital. Am J Psychiatry 152: 453-455.
8. EnVivo-Pharmaceuticals (2009). EnVivo reports positive results of its EVP-6124 clinical biomarker study in schizophrenia patients.
9. EnVivo-Pharmaceuticals (2011). EnVivo announces positive phase 2b clinical data in schizophrenia: EVP 6124 meets primary endpoint with statistically significant improvements in cognition and multiple secondary endpoints for improvement in function and impact on negative symptoms
10. Erhart SM, Marder SR, Carpenter WT (2006). Treatment of schizophrenia negative symptoms: future prospects. Schizophr Bull 32: 234-237.
11. Fleischhacker W (2000). Negative symptoms in patients with schizophrenia with special reference to the primary versus secondary distinction. Encephale 1: 12-14.
12. Freedman R, Coon H, Myles-Worsley M, Orr-Urtreger A, Olincy A, Davis A et al (1997). Linkage of a neurophysiological deficit in schizophrenia to a chromosome 15 locus. Proc Natl Acad Sci USA 94: 587-592.
13. Freedman R, Hall M, Adler LE, Leonard S (1995). Evidence in postmortem brain tissue for decreased numbers of hippocampal nicotinic receptors in schizophrenia. Biol Psychiatry 38: 22-33.
14. Freedman R, Olincy A, Buchanan RW, Harris JG, Gold JM, Johnson L et al (2008). Initial phase 2 trial of a nicotinic agonist in schizophrenia. Am J Psychiatry 165: 1040-1047.
15. Goff DC, Henderson DC, Amico E (1992). Cigarette smoking in schizophrenia: relationship to psychopathology and medication side effects. Am J Psychiatry 149: 1189-1194.
16. Gold JM (2004). Cognitive deficits as treatment targets in schizophrenia. Schizophr Res 72: 21-28.
17. Gray JA, Roth BL (2007). Molecular targets for treating cognitive dysfunction in schizophrenia. Schizophr Bull 33: 1100-1119.
18. Hauser TA, Kucinski A, Jordan KG, Gatto GJ, Wersinger SR, Hesse RA et al (2009). TC-5619: an alpha7 neuronal nicotinic receptorselective agonist that demonstrates efficacy in animal models of the positive and negative symptoms and cognitive dysfunction of schizophrenia. Biochem Pharmacol 78: 803-812.
19. Hawkins BT, Abbruscato TJ, Egleton RD, Brown RC, Huber JD, Campos CR et al (2004). Nicotine increases in vivo blood-brain barrier permeability and alters cerebral microvascular tight junction protein distribution. Brain Res 1027: 48-58.
20. Hughes JR, Hatsukami DK, Mitchell JE, Dahlgren LA (1986). Prevalence of smoking among psychiatric outpatients. Am J Psychiatry 143: 993-997.
21. Kern RS, Nuechterlein KH, Green MF, Baade LE, Fenton WS, Gold JM et al (2008). The MATRICS Consensus Cognitive Battery, part 2: co-norming and standardization. Am J Psychiatry 165: 214-220.
22. Kucinski AJ, Stachowiak MK, Wersinger SR, Lippiello PM, Bencherif M (2011). Alpha7 neuronal nicotinic receptors as targets for novel therapies to treat multiple domains of schizophrenia. Curr Pharm Biotechnol 12: 437-448.
23. Luntz-Leybman V, Bickford PC, Freedman R (1992). Cholinergic gating of response to auditory stimuli in rat hippocampus. Brain Res 587: 130-136.
24. Manda VK, Mittapalli RK, Bohn KA, Adkins CE, Lockman PR (2010). Nicotine and cotinine increases the brain penetration of saquinavir in rat. J Neurochem 115: 1495-1507.
25. Marder SR, Fenton W (2004). Measurement and treatment research to improve cognition in schizophrenia: NIMH MATRICS initiative to support the development of agents for improving cognition in schizophrenia. Schizophr Res 72: 5-9.
26. Mexal S, Berger R, Logel J, Ross RG, Freedman R, Leonard S (2010). Differential regulation of alpha7 nicotinic receptor gene (CHRNA7) expression in schizophrenic smokers. J Mol Neurosci 40: 185-195.
27. Miyamoto S, Duncan GE, Marx CE, Lieberman JA (2005). Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs. Mol Psychiatry 10: 79-104.
28. Nuechterlein KH, Barch DM, Gold JM, Goldberg TE, Green MF, Heaton RK (2004). Identification of separable cognitive factors in schizophrenia. Schizophr Res 72: 29-39.
29. Nuechterlein KH, Green MF, Kern RS, Baade LE, Barch DM, Cohen JD et al (2008). The MATRICS Consensus Cognitive Battery, part 1: test selection, reliability, and validity. Am J Psychiatry 165: 203-213.
30. O'Carroll R (2000). Cognitive impairment in schizophrenia. Adv Psychiatric Treatment 6: 161-168.
31. Ojeda N (2000). Course of cognitive symptoms in schizophrenia: a review of the literature. Actas Esp Psiquiatr 35: 263-270.
32. Olincy A, Harris JG, Johnson LL, Pender V, Kongs S, Allensworth D et al (2006). Proof-of-concept trial of an alpha7 nicotinic agonist in schizophrenia. Arch Gen Psychiatry 63: 630-638.
33. Olincy A, Stevens KE (2007). Treating schizophrenia symptoms with an alpha7 nicotinic agonist, from mice to men. Biochem Pharmacol 74: 1192-1201.
34. Reichenberg A, Caspi A, Harrington H, Houts R, Keefe RS, Murray RM et al (2010). Static and dynamic cognitive deficits in childhood preceding adult schizophrenia: a 30-year study. Am J Psychiatry 167: 160-169.
35. Reichenberg A, Harvey PD (2007). Neuropsychological impairments in schizophrenia: integration of performance-based and brain imaging findings. Psychol Bull 133: 833-858.
36. Ripoll N, Bronnec M, Bourin M (2004). Nicotinic receptors and schizophrenia. Curr Med Res Opin 20: 1057-1074.
37. Stahl SM, Buckley PF (2007). Negative symptoms of schizophrenia: a problem that will not go away. Acta Psychiatr Scand 115: 4-11.
38. Tandon R, Nasrallah HA, Keshavan MS (2009). Schizophrenia, 'just the facts' 4. Clinical features and conceptualization. Schizophr Res 110: 1-23.
39. Tregellas JR, Tanabe J, Rojas DC, Shatti S, Olincy A, Johnson L et al (2011). Effects of an alpha 7-nicotinic agonist on default network activity in schizophrenia. Biol Psychiatry 69: 7-11